|
|
|
|
|
Ergotamine: profile and news
Painful cluster headaches drive sufferer out of bed Mar 1, 2006 Response Properties of Dural Nociceptors in Relation to Headache Feb 21, 2006 Boehringer Ingelheim Announces 48-week Results from Aptivus(R) ... Feb 9, 2006 Boehringer Ingelheim Announces 48-week Results from Aptivus(R) ... 09 Feb 2006 Reduce platelet aggregation, blood clotting, inflammation, nervous ... Jan 12, 2006 William Speed III studied headaches Nov 18, 2005 New Data Show a Kaletra(R) (Lopinavir/Ritonavir)-Based Regimen ... Nov 18, 2005 Boehringer Ingelheim Announces 48-Week Results from Aptivus(R) ... Nov 21, 2005 Experts Sort Fact from Fiction on Health Effects of Mold Nov 8, 2005 Abbott Receives FDA Approval for New Kaletra(R) (Lopinavir ... 31 Oct 2005 Kaletra ® may provide convenient dosages in HIV treatment regime Jul 31, 2005 Treating migraines takes trial and error approach Jul 25, 2005 Abbott Statement on Agreement With Brazilian Government for ... 11 Jul 2005 Valeant Pharmaceuticals Introduces Redesigned Migranal Delivery ... Jun 27, 2005 Valeant Pharmaceuticals Introduces Redesigned Migranal Delivery ... 13 Sep 2002 THE ECONOMIC AND PSYCHOSOCIAL IMPACT OF MIGRAINE BEFORE AND AFTER ... Apr 27, 2005 Prenatal Diagnosis of Polymicrogyria by Fetal Magnetic Resonance ... Apr 19, 2005 Serena Williams Launches 'RALLY for Menstrual Migraine' Campaign ... Apr 12, 2005 Psychedelic medicine: Mind bending, health giving Feb 23, 2005 Other information Indication For use as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants, or so called "histaminic cephalalgia". Pharmacology Ergotamine is a vasoconstrictor and alpha adrenoreceptor antagonist. The pharmacological properties of ergotamine are extremely complex; some of its actions are unrelated to each other, and even mutually antagonistic. The drug has partial agonist and/or antagonist activity against tryptaminergic, dopaminergic and alpha adrenergic receptors depending upon their site, and it is a highly active uterine stimulant. It causes constriction of peripheral and cranial blood vessels and produces depression of central vasomotor centers. The pain of a migraine attack is believed to be due to greatly increased amplitude of pulsations in the cranial arteries, especially the meningeal branches of the external carotid artery. Ergotamine reduces extracranial blood flow, causes a decline in the amplitude of pulsation in the cranial arteries, and decreases hyperperfusion of the territory of the basilar artery. It does not reduce cerebral hemispheric blood flow. Mechanism Of Action Ergotamine acts on migraine by one of two proposed mechanisms: 1) activation of 5-HT1D receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache, and 2) activation of 5-HT1D receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release. Drug Category Adrenergic alpha-Agonists; Analgesics, Non-Narcotic; Vasoconstrictor Agents; Sympatholytics; ATC:N02CA01; ATC:N02CA02 Brand Names/Synonyms D.H.E. 45; Dihydroergotamine Mesylate; Ergomar; Ergostat; Ergotamin; Ergotamine; Ergoton-a [As Succinate]; Medihaler Ergotamine; Migranal; Wigrettes Dosage Forms TABLET Absorption Not Available Interactions Interactions for Ergotamine: The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine. The pressor effects of ERGOMAR and other vasoconstrictor drugs can combine to cause dangerous hypertension. Chemical IUPAC Name Not Available Chemical Formula C33H35N5O5 Half Life 2 hours Drug Type Approved Drug # Accession No APRD00677 CAS Registry Number 113-15-5 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |